Items where Subject is "Australian and New Zealand Standard Research Classification > MEDICAL AND HEALTH SCIENCES (110000) > ONCOLOGY AND CARCINOGENESIS (111200) > Cancer Therapy (excl. Chemotherapy and Radiation Therapy) (111204)"
|Up a level|
- Subjects classification (47368)
- Australian and New Zealand Standard Research Classification (47368)
Group by: Authors/Creators | Item Type
Number of items at this level: 57.
Adamson, R.E., Frazier, A.A., Evans, H., Chambers, Karen F. , Schenk, E., Essand, M., et al. (2012) In vitro primary cell culture as a physiologically relevant method for preclinical testing of human oncolytic adenovirus. Human Gene Therapy, 23(2), pp. 218-230.
Arozarena, Imanol, Sanchez-Laorden, Berta, Packer, Leisl M., Hidalgo-Carcedo, Cristina, Hayward, Robert, Viros, Amaya, et al. (2011) Oncogenic BRAF induces melanoma cell invasion by downregulating the cGMP-specific phosphodiesterase PDE5A. Cancer Cell, 19(1), pp. 45-57.
Barnes, Emma C., Said, Nur Akmarina B.M., Williams, Elizabeth D., Hooper, John N.A., & Davis, Rohan A. (2010) Ecionines A and B, two new cytotoxic pyridoacridine alkaloids from the Australian marine sponge, Ecionemia geodides. Tetrahedron, 66(1), pp. 283-287.
Bisseling, Karin, Kondalsamy-Chennakesavan, Srinivas, Bekkers, Ruud, Janda, Monika, & Obermair, Andreas (2010) Depression, anxiety and body image after treatment for invasive stage one epithelial ovarian cancer. Australian and New Zealand Journal of Obstetrics and Gynecology, 49(6), pp. 660-666.
Busacca, Sara, Sheaff, Michael, Arthur, Kenneth, Gray, Steven G, O'Byrne, Kenneth J., Richard, Derek J., et al. (2012) BRCA1 is an essential mediator of vinorelbine-induced apoptosis in mesothelioma. The Journal of Pathology, 227(2), pp. 200-208.
Byron, Sara A., Loch, David, & Pollock, Pamela M. (2012) Fibroblast growth factor receptor inhibition synergizes with paclitaxel and doxorubicin in endometrial cancer cells. International Journal of Gynecological Cancer, 22(9), pp. 1517-1526.
Byron, Sara A., Loch, David C. , Wellens, Candice L., Wortmann, Andreas, Wu, Jiayi, Wang, John, et al. (2012) Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status. BMC Molecular Cancer, 11(75).
Cathcart, Mary-Clare, Useckaite, Zivile, Drakeford, Clive, Semik, Vikki, Lysaght, Joanne, Gately, Kathy, et al. (2016) Anti-cancer effects of baicalein in non-small cell lung cancer in-vitro and in-vivo. BMC Cancer, 16, Article Number-707.
Chan, Alexandre, Cameron, Michael C., Garden, Benjamin, Boers-Doets, Christine B., Schindler, Katja, Epstein, Joel B., et al. (2015) A systematic review of patient-reported outcome instruments of dermatologic adverse events associated with targeted cancer therapies. Supportive Care in Cancer, 23(8), pp. 2231-2244.
Clark, R.A., Berry, N.M., Chowdhury, M.H., McCarthy, A.L., Ullah, S., Versace, V.L., et al. (2016) Heart failure following cancer treatment: Characteristics, survival and mortality of a linked health data analysis. Internal Medicine Journal, 46(11), pp. 1297-1306.
Davis, I. D., Long, A., Yip, S., Espinoza, D., Thompson, J. F., Kichenadasse, G., et al. (2015) EVERSUN: A phase 2 trial of alternating sunitinib and everolimus as first-line therapy for advanced renal cell carcinoma. Annals of Oncology, 26(6), pp. 1118-1123.
Decatris, Marios P. & O'Byrne, Kenneth J. (2016) Immune checkpoint inhibitors as first-line and salvage therapy for advanced non-small-cell lung cancer. Future Oncology, 12(15), pp. 1805-1822.
DiSipio, Tracey, Hayes, Sandi, Newman, Beth M., & Janda, Monika (2008) Health-related quality of life 18 months after breast cancer : comparison with the general population of Queensland, Australia. Supportive Care in Cancer, 16(10), pp. 1141-1150.
Dong, Ying, Batra, Jyotsna, Anand, Kamal, Bapat, Sharmila, & Clements, Judith A. (2014) Transforming the future of treatment for ovarian cancer. Clinical & Experimental Pharmacology, 4(3), p. 1000157.
de Souza, Paul, Russell, Pamela, Kearsley, John, & Howes, Laurence (2010) Clinical pharmacology of isoflavones and its relevance for potential prevention of prostate cancer. Nutrition Reviews, 68(9), pp. 542-555.
Fuchs, Adrian V., Tse, Brian W.C., Pearce, Amanda K., Yeh, Mei-Chun, Fletcher, Nicholas L., Huang, Steve S., et al. (2015) Evaluation of polymeric nanomedicines targeted to PSMA: Effect of ligand on targeting efficiency. Biomacromolecules, 16(10), pp. 3235-3247.
Fuhrman-Luck, Ruth A., Stansfield, Scott H., Stephens, Carson R., Loessner, Daniela, & Clements, Judith A. (2016) Prostate cancer-associated kallikrein-related peptidase 4 activates matrix metalloproteinase-1 and thrombospondin-1. Journal of Proteome Research, 15(8), pp. 2466-2478.
Galvão, Daniel A., Nosaka, Kazunori, Taafe, Dennis, Peake, Jonathan, Spry, Neil, Suzuki, Katsuhiko, et al. (2008) Endocrine and immune responses to resistance training in prostate cancer patients. Prostate Cancer and Prostatic Diseases, 11(2), pp. 160-165.
Gleave, Martin E., Miyake, Hideaki, Nelson, Colleen, Rennie, Paul, & Leung, Simon (2001) Targeting Antiapoptotic Genes Upregulated by Androgen Withdrawal Using Antisense Oligodeoxynucleotides to Enhance Androgen-and Chemo-Sensitivity in Prostate Cancer. In Chung, Leland W. K., Isaacs, William B., & Simons, Jonathan W. (Eds.) Prostate Cancer: Biology, Genetics, and the New Therapeutics. Humana Press Inc., Totowa, NJ, pp. 327-340.
Gopalan, Vinod, Pillai, Suja, Ebrahimi, Faeza, Salajegheh, Ali, Lam, Tommy C., Le, Tran K., et al. (2014) Regulation of microRNA-1288 in colorectal cancer : altered expression and its clinicopathological significance. Molecular Carcinogenesis, 53 (S1), E36-E44.
Graves, Nicholas, Janda, Monika, Merollini, Katharina, Gebski, Val, & Obermair, Andreas (2013) The cost-effectiveness of total laparoscopic hysterectomy compared to total abdominal hysterectomy for the treatment of early stage endometrial cancer. BMJ Open, 3(4).
Gunter, Jennifer H., Lubik, Amy A., McKenzie, Ian, Pollak, Michael, & Nelson, Colleen C. (2012) The interactions between insulin and androgens in progression to castrate resistant prostate cancer. Advances in Urology, 2012, pp. 1-11.
Hayes, Sandra C. (2009) Exercise and lymphoedema : Is it good or bad? In The 15th UICC Reach to Recovery International Breast Cancer Support Conference, 13-15 May 2009, Brisbane Convention and Exhibition Centre, Brisbane. (Unpublished)
Hollier, Brett G., Evans, KW, & Mani, SA (2009) The epithelial-to-mesenchymal transition and cancer stem cells : a coalition against cancer therapies. Journal of Mammary Gland Biology and Neoplasia, 14(1), pp. 29-43.
Holzapfel, Boris Michael, Wagner, Ferdinand, Thibaudeau, Laure, Levesque, Jean-Pierre, & Hutmacher, Dietmar Werner (2015) Concise review: Humanized models of tumor immunology in the 21st century: Convergence of cancer research and tissue engineering. STEM CELLS, 33(6), pp. 1696-1704.
Irani, Soussan, Salajegheh, Ali, Smith, Robert A., & Lam, Alfred King-Yin (2014) A review of the profile of endothelin axis in cancer and its management. Critical Reviews in Oncology/Hematology, 89(2), pp. 314-321.
Janda, Monika, DiSipio, Tracey, Hurst, Cameron P., Cella, David, & Newman, Beth M. (2008) The Queensland cancer risk study: general population norms for the functional assessment of cancer therapy-general (FACT-G). Psycho-Oncology, 18(6), pp. 606-614.
Janda, Monika, Steginga, Suzanne K., Dunn, Jeff, Langbecker, Danette H., Walker, David, & Eakin, Elizabeth G. (2008) Unmet supportive care needs and interest in services among patients with a brain tumour and their carers. Patient Education and Counseling, 71(2), pp. 251-258.
Jeet, Varinder, Rockstroh, Anja, Lehman, Melanie, & Nelson, Colleen C. (2015) Investigating the role of a potential angiogenic target, YKL40, for the treatment of metastatic prostate cancer. In 2nd Prostate Cancer World Congress, 17-21 August 2015, Cairns Convention Centre, Cairns, Qld.
Jeet, Varinder, Russell, Pamela J., Verma, Nirupama D., & Khatri, Aparajita (2012) Targeting aurora kinases : a novel approach to curb the growth and chemoresistance of androgen refractory prostate cancer. Current Cancer Drug Targets, 12(2), pp. 144-163.
Kolosov, Anton, Aurini, Lucia, Williams, Elizabeth D., Cooke, Ian, & Goodchild, Colin S. (2011) Intravenous injection of leconotide, an omega conotoxin : synergistic antihyperalgesic effects with morphine in a rat model of bone cancer pain. Pain Medicine, 12(6), pp. 923-941.
Kolosov, Anton, Goodchild, Colin S., Williams, Elizabeth D., & Cooke, Ian (2012) Flupirtine enhances the anti-hyperalgesic effects of morphine in a rat model of prostate bone metastasis. Pain Medicine, 13(11), pp. 1444-1456.
Langbecker, Danette H., Janda, Monika, Yates, Patsy, Biggs, Vivien, & Walker, David (2007) Health professionals' perspectives on information delivery for patients newly diagnosed with brain tumours. Asia-Pacific Journal of Clinical Oncology, 3(S2), A49.
Langbecker, Danette H., Janda, Monika, Yates, Patsy, Biggs, Vivien, & Walker, David (2008) How can we better meet the information needs of patients newly diagnosed with brain tumours? In International Psycho-Oncology Society 10th World Congress : Advancing Culturally Diverse Approaches in Psycho-Oncology and Palliative Care, 11-13 June 2008, Madrid. (Unpublished)
Libério, Michelle S., Joanitti, Graziella A., Azevedo, Ricardo B., Cilli, Eduardo M., Zanotta, Lanuse C., Nascimento, Anna C., et al. (2011) Anti-proliferative and cytotoxic activity of pentadactylin isolated from Leptodactylus labyrinthicus on melanoma cells. Amino Acids, 40(1), pp. 51-59.
Libério, Michelle S., Sadowski, Martin, Nelson, Colleen C., & Davis, Rohan A. (2014) Identification of eusynstyelamide B as a potent cell cycle inhibitor following the generation and screening of an ascidian-derived extract library using a real time cell analyzer. Marine Drugs, 12(10), pp. 5222-5239.
Ling, Patrick, Luk, Sze U., Al-Ejeh, Fares, & Khanna, Kum K. (2012) Tocotrienol as potential anticancer agent. Carcinogenesis, 33(2), pp. 233-239.
Maitland, Norman, Chambers, Karen F., Georgopoulos, Lindsay, Simpson-Holley, Martha, Leadley, Regina, Evans, Helen, et al. (2010) Gene transfer vectors targeted to human prostate cancer : do we need better preclinical testing systems? Human Gene Therapy, 21(7), pp. 815-827.
Moon, H., Lee, C.S., Inder, K.L., Sharma, S., Choi, E., Black, D.M., et al. (2013) PTRF/cavin-1 neutralizes non-caveolar caveolin-1 microdomains in prostate cancer. Oncogene, 33(27), pp. 3561-3570.
Mosaad, Eman Mohamed Othman, Chambers, Karen, Clements, Judith, & Doran, Michael (2015) Rethinking stromal cells contribution in the drug screening approach of prostate cancer. In 2nd Prostate Cancer World Congress, 17-21 August 2015, Cairns Convention Centre, Cairns, Qld.
Packer, Leisl M. & Marais, Richard (2011) Unswitch-ABL drugs overcome resistance in chronic myeloid leukemia. Cancer Cell, 19(4), pp. 435-437.
Rahman, Md Atiqur, Salajegheh, Ali, Smith, Robert A., & Lam, Alfred King-yin (2014) BRAF inhibitor therapy for melanoma, thyroid and colorectal cancers : development of resistance and future prospects. Current Cancer Drug Targets, 14(2), pp. 128-143.
Rhee, Handoo, Gunter, Jennifer H., Heathcote, Peter, Ho, Ken, Stricker, Phillip, Corcoran, Niall M., et al. (2015) Adverse effects of androgen-deprivation therapy in prostate cancer and their management. BJU International, 115(S5), pp. 3-13.
Rhee, Handoo, Vela, Ian, Gunter, Jennifer, Jovanovic, Lidija, Hollier, Brett, Williams, Elizabeth, et al. (2015) Clinical application of biomarkers in prostate cancer in men with metabolic syndrome project: Clinical evaluation of prognostic and metabolic benefits of Metformin in prostate cancer. In Urological Society of Australia and New Zealand 68th Annual Scientific Meeting, 11–14 April 2015, Adelaide, Australia.
Rutowski, Raphael, Mertens-Walker, Inga, Lisle, Jessica E, Herington, Adrian C., & Stephenson, Sally-Anne (2012) Evidence for a dual function of EphB4 as tumor promoter and suppressor regulated by the absence or presence of the ephrin-B2 ligand. International Journal of Cancer, 131(5), E614-E624.
Shah, Esha T., Upadhyaya, Akanksha, Philp, Lisa K., Tang, Tiffany, Skalamera, Dubravka, Gunter, Jennifer, et al. (2016) Repositioning “old” drugs for new causes: Identifying new inhibitors of prostate cancer cell migration and invasion. Clinical and Experimental Metastasis, 33(4), pp. 385-399.
Singh, Ben, Newton, Robert, Cormie, Prue, Galvão, Daniel A., Cornish, Bruce, Reul-Hirche, Hildegard, et al. (2015) Effects of compression on lymphoedema during resistance exercise in women with breast cancer-related lymphoedema: A randomised, cross-over trial. Lymphology, 48(2), pp. 80-92.
Singh, Benjamin, Buchan, Jena, Box, Robyn, Janda, Monika, Peake, Jonathan, Purcell, Amanda, et al. (2016) Compression use during an exercise intervention and associated changes in breast cancer-related lymphoedema. Asia-Pacific Journal of Clinical Oncology. (In Press)
Stuchbery, Ryan, Kurganovs, Natalie J., McCoy, Patrick J., Nelson, Colleen C., Hayes, Vanessa M., Corcoran, Niall M., et al. (2015) Target acquired: Progress and promise of targeted therapeutics in the treatment of prostate cancer. Current Cancer Drug Targets, 15(5), pp. 394-405.
Tevz, Gregor, Hossain, Akther, Bock, Nathalie, Jeet, Varinder, Bathgate, Ross A., Williams, Elizabeth D., et al. (2015) Impeding the adaptive response of prostate cancer to androgen targeted therapies with relaxin receptor antagonist. In 2nd Prostate Cancer World Congress, 17-21 August 2015, Cairns Convention Centre, Cairns, Qld.
Trisilowati, , McCue, Scott W., & Mallet, Daniel G. (2013) Numerical solution of an optimal control model of dendritic cell treatment of a growing tumour. ANZIAM Journal, 54, C664-C680.
Uemura, Hirotsugu, Nelson, Colleen, Schalken, Jack A., & Klotz, Laurence (2012) Personalized cancer therapy for urological cancers: From bench to bedside and back. Advances in Urology, 2012(2012), pp. 1-2.
Vela, Ian & Chen, Yu (2015) Prostate cancer organoids: A potential new tool for testing drug sensitivity. Expert Review of Anticancer Therapy, 15(3), pp. 261-263.
Walpole, Carina, Pandey, Saurabh, Cabot, Peter J., Shaw, Paul N., Batra, Jyotsna, & Hewavitharana, Amitha K. (2015) Carica papaya leaf juice extracts have selective anti-proliferative responses in prostatic disease. In 2nd Prostate Cancer World Congress, 17-21 August 2015, Cairns Convention Centre, Cairns, Qld.
Wilkinson, Ray, Woods, Katherine, D'Rozario, Rachael, Prue, Rebecca, Vari, Frank, Hardy, Melinda Y, et al. (2012) Human Kallikrein 4 signal peptide induces cytotoxic T cell responses in healthy donors and prostate cancer patients. Cancer Immunology Immunotherapy, 61(2), pp. 169-179.
Williams, Elizabeth D. & Thompson, Erik W. (2015) How cancer doctors use personalized medicine to target variations unique to each tumour. Conversation.
Yates, Patsy (2008) Cancer. In Chang, Esther & Johnson, Amanda (Eds.) Chronic Illness and Disability : Principles for Nursing Practice. Churchill Livingstone Elsevier, Chatswood, NSW, pp. 424-437.